advertisement
Abstract #23515 Published in IGR 11-2
Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues
Luhtala S; Vaajanen A; Oksala O; Valjakka J; Vapaatalo HJournal of Ocular Pharmacology and Therapeutics 2009; 25: 23-28
PURPOSE: An active local renin-angiotensin system (RAS) has recently been found in the human eye. The aim of the present study was to compare the activities of central RAS enzymes (ACE1 and 2) in porcine ocular tissues, morphologically and physiologically close to the human eye. In addition, the effects of three ACE-inhibitory tripeptides on these enzymes were evaluated. METHODS: Enucleated fresh porcine eyes were used. Activities of ACE1 and ACE2 and their inhibition by bioactive tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) as well as by a standard ACE-inhibitor captopril were assayed in the vitreous body, the retina and the ciliary body using fluorometric detection methods. RESULTS: Activity of ACE1 as well as ACE2 was found in all tissues evaluated. ACE1 activity was markedly higher in the ciliary body (3.7 (plus or minus) 0.7 mU/mg protein) than in retina (0.2 (plus or minus) 0.02 mU/mg), whereas ACE2 activities in the ciliary body (0.2 (plus or minus) 0.02 mU/mg) and retina (0.2 (plus or minus) 0.01 mU/mg) were at the same level. In the vitreous body ACE1 activity (8.2 (plus or minus) 0.31 nmol/min/mL) was manifold compared to that of ACE2 (0.1 (plus or minus) 0.02 nmol/min/mL). The tripeptides inhibited ACE1 at one-thousandth of the concentration needed to inhibit ACE2. All peptides studied evinced about equal inhibitory activities. CONCLUSION: To our knowledge the present findings constitute the first evidence of ACE2 activity in the ciliary and vitreous bodies, in addition to previously described activity in the retina. The known favorable effects of ACE2 products vs. those of ACE1 suggest a counterbalancing interaction of these two enzyme homologues in physiological regulation of ocular circulation and pressure and possible protective role in certain ophthalmic disorders such as glaucoma and diabetic retinopathy.
H. Vapaatalo. Institute of Biomedicine, Pharmacology, University of Helsinki, PO Box 63, 00014 Helsinki, Finland. heikki.vapaatalo@helsinki.fi
Classification:
3.8 Pharmacology (Part of: 3 Laboratory methods)
